Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jsps.2020.06.022 http://scihub22266oqcxt.onion/10.1016/j.jsps.2020.06.022 C7332461!7332461 !32788835     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32788835 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Saudi+Pharm+J 2020 ; 28 (8 ): 1004-1008 Nephropedia Template TP {{tp|p=32788835 |t=2020. COVID-19: Clinical aspects and therapeutics responses |pdf=|usr=}}{{32788835 }} gab.com Text COVID-19: Clinical aspects and therapeutics responses JO: Saudi Pharm J http://www.kidney.de/pget.php?&tw=1&pmid=32788835 #FOAvip COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. Twit Text FOAVip COVID-19: Clinical aspects and therapeutics responses ????Saudi Pharm J http://www.kidney.de/pget.php?&tw=1&pmid=32788835 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32788835 #FOAvip English Wikipedia <ref>{{Cite pmid|32788835 }}</ref> COVID-19: Clinical aspects and therapeutics responses #MMPMID32788835 Khan S ; Ali A ; Shi H ; Siddique R ; Shabana ; Nabi G ; Hu J ; Wang T ; Dong M ; Zaman W ; Han G Saudi Pharm J 2020[Aug]; 28 (8 ): 1004-1008 PMID32788835 show ga COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. ?COVID-19: Clinical aspects and therapeutics responses (epmc).pdf DeepDyve Pubget Overpricing